BACKGROUND
Diagnosis: Metastatic poorly differentiated non-small cell lung adenocarcinoma (NSCLC)
Primary tumor: Right lower lobe
Stage: Advanced metastatic disease
Documented Metastatic Spread (PET-CT, 23 April 2025)
- Lymph nodes: Bilateral lower cervical, mediastinal, bilateral hilar
- Lungs: Bilateral hematogenous pulmonary metastases (sub-centimeter)
- Liver: Multiple centrally hypodense metastatic lesions
- Bone: Scattered sclerotic and mixed osseous lesions (vertebra, pelvic bone)
- Additional: Possible perilymphatic spread in right lower lobe
This represents a high-burden, poorly differentiated metastatic lung cancer, typically associated with rapid progression, severe inflammation, high LDH, anemia, bone involvement, and hypercoagulability.
The patient has been following Targeted Metabolic Therapy for 4 months, with serial labs showing a consistent, multi-system biochemical transformation.
One-Month Setback (October)
In October, the patient experienced a temporary digestive setback (diarrhea), nausea and weakness requiring dietary adjustment and partial protocol pause.
Despite this interruption, key cancer, bone, inflammatory, and coagulation markers continued to improve, indicating durable metabolic control rather than fragile suppression.
4-MONTH BIOMARKER EVOLUTION
Bloodwork Timeline (Aug → Dec 2025)
| Marker | Aug | Sep | Oct | Dec | Net Change |
|---|---|---|---|---|---|
| Hemoglobin (g/dL) | 9.3 | 10.9 | 10.1 | 12.3 | +32% |
| Platelets | 463 | 196 | 216 | 246 | Normalized |
| Lymphocytes % | 13% | 34% | 17% | 24% | Improved |
| ESR | 38 | 15 | 28 | 7 | –82% |
| CRP (mg/L) | 98 | 2.3 | 6.4 | 3.7 | –96% |
| LDH (U/L) | 911 | 234 | 197 | 201 | –78% |
| ALP (U/L) | 132 | 170 | 84 | 46 | –65% |
| D-Dimer | 2063 | 1550 | 1280 | 830 | –60% |
| Iron | 18 | 59 | 37 | 199 | Repleted |
| Vitamin D (ng/mL) | 21 | 50 | 54 | 56 | Optimized |
| CYFRA 21-1 | 7.57 | — | 1.7 | — | –78% |
| CA-125 | 100 | — | 11.9 | 9.88 | –90% |
| CEA | 24.6 | 41.6 | 44 | 42 | Stable |
| HbA1c (%) | 5.1 | 5.1 | 5.0 | 5.2 | Optimal |
| Glucose (mg/dL) | 84 | 89 | 94 | — | Normal |
INTERPRETATION
This patient started therapy with multiple negative prognostic indicators:
- Poorly differentiated histology
- Liver and bone metastases
- Severe systemic inflammation
- Marked anemia
- Very high LDH
- Elevated ALP (bone activity)
- Marked hypercoagulability (D-dimer >2000)
After 4 months of Targeted Metabolic Therapy, the biochemical pattern shows:
1. Tumor metabolic activity sharply reduced
- LDH ↓ ~78%
- CYFRA 21-1 ↓ ~78%
- CA-125 ↓ ~90%
2. Bone metastatic activity significantly suppressed
- ALP ↓ ~65% (170 → 46)
This supports reduced skeletal tumor turnover and improved bone metabolic stability.
3. Hypercoagulable cancer state markedly improved
- D-dimer ↓ ~60% (2063 → 830)
This reflects lower tumor-driven coagulation activation, a key survival factor in advanced NSCLC.
4. Inflammation collapsed
- CRP ↓ 96%
- ESR ↓ 82%
5. Systemic recovery
- Hemoglobin restored to normal range
- Platelets normalized
- Lymphocyte profile improved
- Iron and vitamin D optimized
6. Metabolic stability maintained
- Normal glucose and HbA1c
- No rebound despite temporary October interruption
Together, these changes strongly indicate true disease stabilization with reduced tumor, bone, and clotting activity, not transient laboratory fluctuation.
PROTOCOL HIGHLIGHTS (CORE DRIVERS)
- Strict ketogenic metabolic therapy mostly animal-based
- Intermittent fasting (16:8) + extended fasting on drug-off days
- Repurposed drug backbone: Fenbendazole, Ivermectin (weight-based), Itraconazole, CDS
- Key anti-cancer adjuncts: High-dose melatonin, curcumin + quercetin, modified citrus pectin, medicinal mushrooms, cannabinoids
- Anti-inflammatory & anti-clot focus: Omega-3 / black seed oil, aspirin, fibrinolytic enzymes
OVERALL ASSESSMENT
In a cancer subtype where rapid progression, bone complications, thrombosis, and decline are expected, this patient demonstrates:
- Sustained suppression of tumor activity
- Significant reduction in bone metastatic turnover
- Marked improvement in cancer-related hypercoagulability
- Reversal of anemia and inflammation
- Durable metabolic and immune stability
This pattern is highly consistent with effective metabolic control of aggressive metastatic NSCLC.
NEXT STEP
- Continue the current metabolic strategy with digestive optimization
- Maintain low LDH, ALP, CRP, and D-dimer as primary monitoring targets
- Repeat PET-CT or MRI to correlate biochemical response with tumor and bone burden
- Continue monthly surveillance of LDH, ALP, D-dimer, CRP, CYFRA 21-1, CA-125, CBC, liver profile
This represents a strong, multi-system metabolic response in poorly differentiated metastatic NSCLC.
